Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Highlights to be presented at Novo’s Capital Markets Day 2026

globenewswire.com
NVO The article discusses Novo Nordisk's Capital Markets Day, focusing on corporate strategy, R&D, commercial strategy, manufacturing, and financials. It outlines strategic ambitions for 2030, including pipeline growth, sustainable growth, and attractive returns. The tone is informative and forward-looking, without explicit positive or negative performance indicators. LLY Eli Lilly is mentioned as an industry peer to Novo Nordisk in the context of strategic ambitions and potential competition. The mention is purely comparative and does not offer specific sentiment about Eli Lilly's performance or prospects. AZN AstraZeneca is mentioned as an industry peer to Novo Nordisk. The mention is purely comparative and does not offer specific sentiment about AstraZeneca's performance or prospects. GILD Gilead Sciences is mentioned as an industry peer to Novo Nordisk. The mention is purely comparative and does not offer specific sentiment about Gilead Sciences' performance or prospects. JNJ Johnson & Johnson is mentioned as an industry peer to Novo Nordisk. The mention is purely comparative and does not offer specific sentiment about Johnson & Johnson's performance or prospects. ABBV AbbVie is mentioned as an industry peer to Novo Nordisk. The mention is purely comparative and does not offer specific sentiment about AbbVie's performance or prospects. NVS Novartis is mentioned as an industry peer to Novo Nordisk. The mention is purely comparative and does not offer specific sentiment about Novartis' performance or prospects. SAN Sanofi is mentioned as an industry peer to Novo Nordisk. The mention is purely comparative and does not offer specific sentiment about Sanofi's performance or prospects. ROG Roche is mentioned as an industry peer to Novo Nordisk. The mention is purely comparative and does not offer specific sentiment about Roche's performance or prospects. GSK GSK plc is mentioned as an industry peer to Novo Nordisk. The mention is purely comparative and does not offer specific sentiment about GSK's performance or prospects. AMGN Amgen is mentioned as an industry peer to Novo Nordisk. The mention is purely comparative and does not offer specific sentiment about Amgen's performance or prospects. MRK Merck & Co. is mentioned as an industry peer to Novo Nordisk. The mention is purely comparative and does not offer specific sentiment about Merck & Co.'s performance or prospects. REGN Biogen is mentioned as an industry peer to Novo Nordisk. The mention is purely comparative and does not offer specific sentiment about Biogen's performance or prospects. PFE Pfizer is mentioned as an industry peer to Novo Nordisk. The mention is purely comparative and does not offer specific sentiment about Pfizer's performance or prospects. BMY Bristol Myers Squibb is mentioned as an industry peer to Novo Nordisk. The mention is purely comparative and does not offer specific sentiment about Bristol Myers Squibb's performance or prospects.

Highlights to be presented at Novo’s Capital Markets Day 2026 Bagsværd, Denmark, 21 September 2026 – Novo Nordisk is today hosting a Capital Markets Day (CMD) in London, where the company is providing an update to its Corporate strategy and strategic ambitions for 2030 1.

During the day, Novo senior management presentations will cover Corporate strategy, R&D strategy, where to play and how to win across therapy areas, Commercial strategy in the US and International Operations, Global Manufacturing & Supply and Financials.

Key highlights of the strategic ambitions for 2030 1 are:

Grow and diversify pipeline

Drive sustainable growth

Deliver attractive returns

All sessions of the CMD are webcast live, and a replay will be made available in the investor section of novonordisk.com. Presentation material from the CMD will also be available throughout the day in the investor section of novonordisk.com.

Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, approximately 66,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube.

This press release may contain certain forward-looking statements relating to the operating, research & development, financial and sustainability performance and results of Novo and/or the industry in which it operates. By their very nature, forward-looking statements involve risks, uncertainties and assumptions, both general and specific, and actual results may differ materially from those contemplated, expressed or implied by any forward-looking statement. Please refer to: http://novonordisk.com/news-and-media/news-and-ir-materials/news-details/forward-looking-statement-cmd-2026.html for further information.

Contacts for further information

1 All ambitions are by 2030 from a 2026 baseline, they are inherently uncertain and do not constitute Novo’s financial outlook or guidance; revenue and margin ambitions are all based on adjusted metrics; CAGR: Compound annual growth rate; Industry peers: Eli Lilly, AstraZeneca, Gilead, Johnson & Johnson, AbbVie, Novartis, Sanofi, Roche, GSK, Amgen, Merck & Co, Biogen, Pfizer, Bristol Myers Squibb

2 >150 bDKK ambition is risk-adjusted and includes current pipeline assets

3 Enter or complete, including new and current programmes; TA: Therapy areas

Attachment